Pencil Biosciences develops a proprietary, modular gene editing and modulation platform that is non‑CRISPR in composition and significantly smaller than Cas‑based technologies. The company intends to deepen and widen the capabilities of its platform to catalyse new therapeutic options for patients with rare diseases and cancer. Pencil describes its technology as modular in design and focused on editing and modulation applications across a range of uses. The startup is led by CEO Dr. Amanda Smith, with primary founder and CTO Dr. Rajik Ibrahim and Chair Dr. Jon Moore. Founded in 2019, the company is pursuing further development of its platform using newly raised funds. Financial operating metrics were not disclosed in the article.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2023